Clinical Data S16 Ep52: Medical Crossfire: PD-L1 Inhibition in Advanced Cutaneous Squamous Cell Carcinoma — Mechanistic Rationale and Clinical Application pharminent April 15, 2026
Regulatory MSD, Daiichi Sankyo’s ifinatamab deruxtecan receives FDA priority pharminent April 14, 2026
Regulatory MSD, Daiichi Sankyo’s ifinatamab deruxtecan receives FDA priority pharminent April 14, 2026
Clinical Data Allogene data suggest ‘off-the-shelf’ CAR-T could delay relapse in lymphoma pharminent April 13, 2026
Clinical Data Allogene stock sails after CAR T clears residual lymphoma in early data cut pharminent April 13, 2026
Clinical Data Revolution rises 40% as pancreatic cancer drug doubles survival pharminent April 13, 2026
Regulatory IDEAYA and Servier’s eye cancer drug heads to FDA after delivering ‘best in class’ efficacy pharminent April 13, 2026
Regulatory FDA issues complete response letter to Replimune’s RP1 for melanoma pharminent April 13, 2026
Regulatory FDA issues complete response letter to Replimune’s RP1 for melanoma pharminent April 13, 2026
M&A / Deals Oricell closes a ‘pre-IPO’ megaround to aim CAR-T at solid tumors pharminent April 10, 2026
M&A / Deals Roche and C4 Therapeutics to advance degrader-antibody conjugates research pharminent April 10, 2026
Other Precision Medicine in Early Oncology Trials: Biomarkers as Strategic Drivers pharminent April 10, 2026
M&A / Deals Novartis-backed Sidewinder collects $137M series B to strike at difficult-to-treat tumors pharminent April 9, 2026
M&A / Deals Sidewinder pockets $137m in Series B to take bispecific ADCs to clinic pharminent April 8, 2026
Clinical Data CatalYm begins phase 2b trial of visugromab in second-line liver cancer treatment pharminent April 7, 2026
Regulatory MSD secures EC clearance for Keytruda combination therapy for ovarian cancer pharminent April 6, 2026
Regulatory S16 Ep43: FDA Approval Insights: Rucaparib for BRCA Mutation-Associated mCRPC: With David Morris, MD, FACS; and Alan H. Bryce, MD pharminent March 31, 2026
Other S16 Ep42: Variability and Innovation in Small Cell Lung Cancer Care: With Ticiana Leal, MD pharminent March 31, 2026
Regulatory S16 Ep40: FDA Approval Insights: Zongertinib for HER2 TKD-Mutated NSCLC: With Julia Rotow, MD; and Martin Dietrich, MD, PhD pharminent March 30, 2026
Other S16 Ep38: Live Tumor Board: Precision Pathways Transforming Patient Care in Advanced NSCLC pharminent March 27, 2026
